/
Other
Neoadjuvant
30
Pipeline Programs↗
20
Active Trials↗
19
Companies Involved↗
Neoadjuvant is an emerging landscape with 30 programs across 19 companies. The most active players are Qilu Pharmaceutical Co., Ltd.. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 11
Phase 223
Phase 35
Approved
No programs
Analysis
Modality Breakdown
70%
Small molecule
21 of 30 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.
Analysis
Trial Status
55
clinical trials
Completed16 · 29%
Recruiting14 · 25%
Terminated9 · 16%
Unknown status7 · 13%
Active, not recruiting6 · 11%
Withdrawn3 · 5%
Clinical Trials
Trial Activity
55 trials
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
Recruiting·—·Phase 1·NCT05839119·32 enrolled
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Recruiting·—·Phase 2·NCT07016399·51 enrolled
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04848116·24 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)